Dentium (A145720) Q4 2024 earnings summary

Executive summary

• Received an unqualified audit opinion for the 2024 and 2023 financial statements, confirming fair presentation under K-IFRS and effective internal controls as of year-end 2024.

• The company operates primarily in dental medical device manufacturing, with a strong global presence and diversified customer base.

Financial highlights

• Revenue for 2024 was ₩320.7 billion, up 1% year-over-year from ₩317.5 billion in 2023.

• Operating income dropped to ₩70.6 billion from ₩111.6 billion year-over-year, reflecting higher costs and expenses.

• Net income for 2024 was ₩26.7 billion, down from ₩72.6 billion in 2023.

• Gross margin decreased as cost of goods sold rose to ₩143.4 billion from ₩120.9 billion year-over-year.

• Basic and diluted EPS for 2024 was ₩3,100, compared to ₩8,416 in 2023.

• Cash and cash equivalents at year-end 2024 were ₩23.1 billion, down from ₩38.9 billion at the end of 2023.

Outlook and guidance

• No explicit forward-looking guidance provided, but the company continues to invest in global expansion and product development.